Liquidia (NASDAQ:LQDA) Lowered to Hold Rating by Wall Street Zen

Wall Street Zen cut shares of Liquidia (NASDAQ:LQDA) from a buy rating to a hold rating in a research note released on Sunday morning.

LQDA has been the subject of a number of other research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Liquidia in a research report on Wednesday, October 8th. Zacks Research upgraded Liquidia from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, January 13th. HC Wainwright upped their price target on Liquidia from $35.00 to $50.00 and gave the stock a “buy” rating in a report on Tuesday, November 4th. Jefferies Financial Group raised their price objective on Liquidia from $45.00 to $55.00 and gave the company a “buy” rating in a report on Tuesday, January 13th. Finally, Wells Fargo & Company initiated coverage on Liquidia in a research report on Monday, October 20th. They issued an “overweight” rating and a $31.00 price objective for the company. Two investment analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $39.67.

Liquidia Trading Down 2.2%

Liquidia stock opened at $37.93 on Friday. The company has a debt-to-equity ratio of 6.19, a quick ratio of 1.96 and a current ratio of 2.20. The stock has a market cap of $3.30 billion, a PE ratio of -26.34, a price-to-earnings-growth ratio of 0.64 and a beta of 0.48. The stock has a 50-day moving average of $32.91 and a two-hundred day moving average of $26.14. Liquidia has a one year low of $11.26 and a one year high of $41.57.

Liquidia (NASDAQ:LQDA) last issued its earnings results on Monday, November 3rd. The company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.41. Liquidia had a negative return on equity of 296.78% and a negative net margin of 176.04%.The company had revenue of $54.34 million during the quarter, compared to analyst estimates of $18.86 million. The business’s revenue for the quarter was up 1106.7% compared to the same quarter last year. On average, research analysts anticipate that Liquidia will post -1.51 EPS for the current fiscal year.

Insider Activity at Liquidia

In other news, CEO Roger Jeffs sold 66,610 shares of the stock in a transaction on Monday, January 12th. The stock was sold at an average price of $37.43, for a total transaction of $2,493,212.30. Following the completion of the transaction, the chief executive officer directly owned 1,037,528 shares in the company, valued at approximately $38,834,673.04. This represents a 6.03% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Jason Adair sold 35,656 shares of the company’s stock in a transaction that occurred on Tuesday, November 18th. The stock was sold at an average price of $30.03, for a total transaction of $1,070,749.68. Following the completion of the transaction, the insider owned 174,998 shares in the company, valued at approximately $5,255,189.94. This represents a 16.93% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 323,354 shares of company stock valued at $11,046,731 over the last ninety days. Corporate insiders own 26.50% of the company’s stock.

Institutional Investors Weigh In On Liquidia

A number of hedge funds have recently bought and sold shares of the stock. Skandinaviska Enskilda Banken AB publ purchased a new stake in Liquidia during the third quarter worth $30,000. FNY Investment Advisers LLC acquired a new position in Liquidia in the third quarter valued at $34,000. NewEdge Advisors LLC purchased a new position in shares of Liquidia during the 2nd quarter worth about $25,000. Steward Partners Investment Advisory LLC grew its stake in shares of Liquidia by 24.0% during the 2nd quarter. Steward Partners Investment Advisory LLC now owns 6,200 shares of the company’s stock valued at $77,000 after buying an additional 1,200 shares during the period. Finally, Tower Research Capital LLC TRC lifted its position in Liquidia by 281.2% during the second quarter. Tower Research Capital LLC TRC now owns 6,679 shares of the company’s stock valued at $83,000 after buying an additional 4,927 shares in the last quarter. Institutional investors and hedge funds own 64.54% of the company’s stock.

Liquidia News Summary

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Unusually large call-option activity: investors bought roughly 54,585 call options on Friday (about +375% vs. average call volume), which can indicate bullish bets or hedging by traders expecting upside in the near term.
• Positive Sentiment: Zacks upgraded LQDA from “hold” to “strong-buy,” a catalyst that can attract momentum-oriented investors and buy-side interest. Read More.
• Neutral Sentiment: Laughing Water Capital mentioned Liquidia in its Q4 2025 investor letter; the hedge fund reported modest positive returns for the quarter and year but the update does not directly signal a change in corporate fundamentals. Read More.
• Neutral Sentiment: Liquidia presented at the 44th Annual J.P. Morgan Healthcare Conference (transcript available); investor takeaways depend on specifics from the presentation (pipeline, commercial progress, guidance). Presentation transcripts tend to be informational until new data or guidance is revealed. Read More.
• Negative Sentiment: Multiple sizable insider sales were reported today across several filings — these include trades totaling roughly $507k, $768k, $493k and $791k (individual links below). Large, clustered insider selling can create near-term selling pressure and raise investor concern about insiders reducing exposure. Read More. Read More. Read More. Read More.
• Negative Sentiment: Additional insider transactions: the CAO sold shares worth ~$413k. Separate filing: director/executive Roger Jeffs sold 66,610 shares — both filings can be perceived negatively by the market. Read More. Read More.

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).